CRISPR Therapeutics AG(CRSP)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CRSP CRISPR Therapeutics AG

盘前交易 07-03 04:31:56 EDT

53.12

-0.83

-1.55%

最高53.98	最低52.52	成交量105.90万
今开53.98	昨收53.95	日振幅2.71%
总市值45.10亿	流通市值44.28亿	总股本8,492万
成交额5,614万	换手率1.27%	流通股本8,337万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"CRSP","market":"US","secType":"STK","nameCN":"CRISPR Therapeutics AG","latestPrice":53.115,"timestamp":1719950400000,"preClose":53.95,"halted":0,"volume":1058986,"delay":0,"floatShares":83369314,"shares":84918093,"eps":-2.724255,"marketStatus":"盘前交易","marketStatusCode":1,"change":-0.835,"latestTime":"07-03 04:31:56 EDT","open":53.98,"high":53.98,"low":52.52,"amount":56138748.73987,"amplitude":0.027062,"askPrice":60.78,"askSize":100,"bidPrice":50,"bidSize":25,"shortable":3,"etf":0,"ttmEps":-2.724255,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1720013400000},"adr":0,"listingDate":1476849600000,"adjPreClose":53.115,"adrRate":0,"postHourTrading":{"tag":"盘后","latestPrice":53.36,"preClose":53.115,"latestTime":"19:47 EDT","volume":26353,"amount":1399745.255,"timestamp":1719964068374},"volumeRatio":0.9184260379252244,"impliedVol":0.5692,"impliedVolPercentile":0.1793},"requestUrl":"/m/hq/s/CRSP","defaultTab":"news","newsList":[{"id":"2445233050","title":"超越CRISPR，精确切割靶点插入序列，新基因编辑工具SeekRNA面世","url":"https://stock-news.laohu8.com/highlight/detail?id=2445233050","media":"中国科技网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445233050?lang=zh_cn&edition=full","pubTime":"2024-06-24 17:10","pubTimestamp":1719220206,"startTime":"0","endTime":"0","summary":"如今，澳大利亚悉尼大学生命与环境科学学院团队成功开发出一种比CRISPR更准确、更灵活的基因编辑工具SeekRNA。SeekRNA则能在不使用任何其他蛋白的情况下，精确切割靶点并插入新DNA序列。这使其相对CRISPR来说更加精确可靠，减少了潜在错误。利用这一特性，seekRNA能适应任何基因组序列，并以精确方式插入新DNA。目前，研究人员已经在细菌中成功测试了seekRNA的有效性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8afemzyGQAK","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["CRSP","LU1861558580.USD","BK4139","BK4556","BK4585","LU1861559042.SGD","BK4588"],"gpt_icon":0},{"id":"2442310030","title":"Crispr Therapeutics Ag盘中异动 下午盘快速上涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2442310030","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442310030?lang=zh_cn&edition=full","pubTime":"2024-06-12 02:21","pubTimestamp":1718130068,"startTime":"0","endTime":"0","summary":"北京时间2024年06月12日02时21分，Crispr Therapeutics Ag股票出现波动，股价大幅上涨5.00%。Crispr Therapeutics Ag股票所在的生物技术行业中，整体涨幅为0.01%。Crispr Therapeutics Ag公司简介：Crispr Therapeutics 是一家基因编辑公司，专注于开发基于 CRISPR/Cas9 的疗法。Crispr 的第一个获批药物是 Casgevy，该药物是与 Vertex Pharmaceuticals 合作开发的，针对镰状细胞病和输血依赖性β地中海贫血，这些疾病的医疗需求尚未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240612022109aef45f86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240612022109aef45f86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4556","BK4139","LU1861558580.USD","BK4585","CRSP","LENZ","LU1861559042.SGD","BK4588"],"gpt_icon":0},{"id":"2440128599","title":"Intellia Therapeutics公布了正在进行的Ntla-2002的1期研究的积极长期数据Ntla-2002是一种用于遗传性血管性水肿（Hae）的在研CRISPR基因编辑疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2440128599","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440128599?lang=zh_cn&edition=full","pubTime":"2024-06-02 20:05","pubTimestamp":1717329953,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics公布了正在进行的Ntla-2002的1期研究的积极长期数据Ntla-2002是一种用于遗传性血管性水肿（Hae）的在研CRISPR基因编辑疗法","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406022005539f11ff88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406022005539f11ff88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4556","NTLA","CRSP","BK4535","BK4139","LENZ","LU1861559042.SGD","BK4585","LU1861558580.USD","BK4588"],"gpt_icon":0},{"id":"2437796946","title":"花旗：维持CRISPR Therapeutics(CRSP.US)评级，由买入调整至买入评级, 目标价由89.00美元调整至84.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2437796946","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437796946?lang=zh_cn&edition=full","pubTime":"2024-05-24 01:35","pubTimestamp":1716485720,"startTime":"0","endTime":"0","summary":"花旗：维持CRISPR Therapeutics(CRSP.US)评级，由买入调整至买入评级, 目标价由89.00美元调整至84.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405240135229ede4307&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405240135229ede4307&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["C","LENZ","CRSP"],"gpt_icon":0},{"id":"2437291591","title":"Crispr Therapeutics Ag盘中异动 急速上涨5.00%报57.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2437291591","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437291591?lang=zh_cn&edition=full","pubTime":"2024-05-22 22:22","pubTimestamp":1716387779,"startTime":"0","endTime":"0","summary":"北京时间2024年05月22日22时22分，Crispr Therapeutics Ag股票出现异动，股价大幅上涨5.00%。截至发稿，该股报57.50美元/股，成交量21.3249万股，换手率0.25%，振幅5.48%。Crispr Therapeutics Ag股票所在的生物技术行业中，整体涨幅为0.24%。Crispr Therapeutics Ag公司简介：Crispr Therapeutics 是一家基因编辑公司，专注于开发基于 CRISPR/Cas9 的疗法。Crispr 的第一个获批药物是 Casgevy，该药物是与 Vertex Pharmaceuticals 合作开发的，针对镰状细胞病和输血依赖性β地中海贫血，这些疾病的医疗需求尚未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240522222259941e9749&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240522222259941e9749&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4588","BK4556","BK4139","CRSP","LU1861558580.USD","LU1861559042.SGD","BK4585"],"gpt_icon":0},{"id":"2435145386","title":"张锋公司又被收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2435145386","media":"经济观察网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435145386?lang=zh_cn&edition=full","pubTime":"2024-05-16 09:49","pubTimestamp":1715824140,"startTime":"0","endTime":"0","summary":"近日，基因编辑公司Arbor Biotechnologies宣布收购一家基因编辑初创公司Serendipity Biosciences。Arbor将获得后者现有的创新资产，包括基于Fanzor、IsrB和其他未公开的可编程编辑技术，补充和扩展了其现有的编辑能力。双方并未公布具体财务细节。　　其中，在Arbor和Serendipity的创始团队中，都能看到联合创始人张锋的身影。Arbor由张锋和哈佛大学David Walt博士等共同创立，Serendipity则是由张锋联合麻省理工学院科学家一同创立。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/yjdt/2024-05-16/doc-inavkuir2279266.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/yjdt/2024-05-16/doc-inavkuir2279266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1861558580.USD","CRSP","BK4139","BK4588","LU1861559042.SGD","BK4556","BK4585"],"gpt_icon":0},{"id":"2435373920","title":"Crispr Therapeutics Ag盘中异动 早盘股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2435373920","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435373920?lang=zh_cn&edition=full","pubTime":"2024-05-13 21:35","pubTimestamp":1715607318,"startTime":"0","endTime":"0","summary":"北京时间2024年05月13日21时35分，Crispr Therapeutics Ag股票出现波动，股价大幅拉升5.00%。Crispr Therapeutics Ag股票所在的生物技术行业中，整体涨幅为0.90%。Crispr Therapeutics Ag公司简介：Crispr Therapeutics 是一家基因编辑公司，专注于开发基于 CRISPR/Cas9 的疗法。Crispr 的第一个获批药物是 Casgevy，该药物是与 Vertex Pharmaceuticals 合作开发的，针对镰状细胞病和输血依赖性β地中海贫血，这些疾病的医疗需求尚未得到满足。该信息摘要如下：奥本海默：维持CRISPR Therapeutics评级，由优于大市调整至优于大市评级, 目标价由102.00美元调整至95.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405132135197a599aa6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405132135197a599aa6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4585","LU1861558580.USD","LU1861559042.SGD","CRSP","BK4139","BK4588","BK4556"],"gpt_icon":0},{"id":"2434864897","title":"奥本海默：维持CRISPR Therapeutics(CRSP.US)评级，由优于大市调整至优于大市评级, 目标价由102.00美元调整至95.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2434864897","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434864897?lang=zh_cn&edition=full","pubTime":"2024-05-11 00:55","pubTimestamp":1715360121,"startTime":"0","endTime":"0","summary":"奥本海默：维持CRISPR Therapeutics(CRSP.US)评级，由优于大市调整至优于大市评级, 目标价由102.00美元调整至95.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405110055228751854d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405110055228751854d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRSP","LENZ"],"gpt_icon":0},{"id":"2434134540","title":"Needham：维持CRISPR Therapeutics(CRSP.US)评级，由买入调整至买入评级, 目标价由90.00美元调整至88.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2434134540","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434134540?lang=zh_cn&edition=full","pubTime":"2024-05-09 21:46","pubTimestamp":1715262388,"startTime":"0","endTime":"0","summary":"Needham：维持CRISPR Therapeutics(CRSP.US)评级，由买入调整至买入评级, 目标价由90.00美元调整至88.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405092146328aed16cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405092146328aed16cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","CRSP"],"gpt_icon":0},{"id":"2433741881","title":"朝气蓬勃的千亿新赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2433741881","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433741881?lang=zh_cn&edition=full","pubTime":"2024-05-08 18:56","pubTimestamp":1715165803,"startTime":"0","endTime":"0","summary":"还能追吗？","market":"sg","thumbnail":"https://img3.gelonghui.com/134a9-c01674fa-e7e7-495e-abd9-02ae3ddc6182.jpg?guru_height=800&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/134a9-c01674fa-e7e7-495e-abd9-02ae3ddc6182.jpg?guru_height=800&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/727759","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["AMRSQ","ZY","BK4139","BK4588","CAGR","BK0226","BK4539","LU1861559042.SGD","CRSP","BK4090","BK4556","BK4109","LU1861558580.USD","603739","BK4585","BK4159"],"gpt_icon":0},{"id":"2432706659","title":"Crispr Therapeutics Ag盘中异动 早盘大幅上涨5.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432706659","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432706659?lang=zh_cn&edition=full","pubTime":"2024-05-03 21:31","pubTimestamp":1714743060,"startTime":"0","endTime":"0","summary":"北京时间2024年05月03日21时31分，Crispr Therapeutics Ag股票出现波动，股价快速拉升5.27%。Crispr Therapeutics Ag股票所在的生物技术行业中，整体涨幅为0.06%。Crispr Therapeutics Ag公司简介：Crispr Therapeutics 是一家基因编辑公司，专注于开发基于 CRISPR/Cas9 的疗法。Crispr 的第一个获批药物是 Casgevy，该药物是与 Vertex Pharmaceuticals 合作开发的，针对镰状细胞病和输血依赖性β地中海贫血，这些疾病的医疗需求尚未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405032131007a57fb05&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405032131007a57fb05&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1861558580.USD","BK4556","CRSP","LU1861559042.SGD","BK4588","BK4139","BK4585","LENZ"],"gpt_icon":0},{"id":"2432357526","title":"Crispr Therapeutics Ag盘中异动 快速上涨5.00%报55.64美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432357526","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432357526?lang=zh_cn&edition=full","pubTime":"2024-05-02 02:58","pubTimestamp":1714589915,"startTime":"0","endTime":"0","summary":"北京时间2024年05月02日02时58分，Crispr Therapeutics Ag股票出现异动，股价快速上涨5.00%。截至发稿，该股报55.64美元/股，成交量78.0638万股，换手率0.92%，振幅5.36%。Crispr Therapeutics Ag股票所在的生物技术行业中，整体涨幅为2.21%。Crispr Therapeutics Ag公司简介：Crispr Therapeutics 是一家基因编辑公司，专注于开发基于 CRISPR/Cas9 的疗法。Crispr 的第一个获批药物是 Casgevy，该药物是与 Vertex Pharmaceuticals 合作开发的，针对镰状细胞病和输血依赖性β地中海贫血，这些疾病的医疗需求尚未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405020258357925a4f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405020258357925a4f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRSP","BK4556","LU1861559042.SGD","BK4588","LENZ","BK4585","LU1861558580.USD"],"gpt_icon":0},{"id":"2430287896","title":"Crispr Therapeutics Ag盘中异动 股价大跌5.03%报52.85美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430287896","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430287896?lang=zh_cn&edition=full","pubTime":"2024-04-25 22:41","pubTimestamp":1714056060,"startTime":"0","endTime":"0","summary":"北京时间2024年04月25日22时41分，Crispr Therapeutics Ag股票出现波动，股价快速跳水5.03%。截至发稿，该股报52.85美元/股，成交量36.7655万股，换手率0.43%，振幅2.32%。Crispr Therapeutics Ag股票所在的生物技术行业中，整体跌幅为1.86%。Crispr Therapeutics Ag公司简介：Crispr Therapeutics 是一家基因编辑公司，专注于开发基于 CRISPR/Cas9 的疗法。Crispr 的第一个获批药物是 Casgevy，该药物是与 Vertex Pharmaceuticals 合作开发的，针对镰状细胞病和输血依赖性β地中海贫血，这些疾病的医疗需求尚未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042522410087e83c52&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042522410087e83c52&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4556","BK4588","LU1861558580.USD","BK4139","LENZ","CRSP","BK4585","LU1861559042.SGD"],"gpt_icon":0},{"id":"2429554486","title":"AI能够重写人类基因组了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2429554486","media":"新智元","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429554486?lang=zh_cn&edition=full","pubTime":"2024-04-24 16:03","pubTimestamp":1713945799,"startTime":"0","endTime":"0","summary":"全球首个基因编辑器开源了","market":"sg","thumbnail":"https://img.huxiucdn.com/article/cover/202404/24/134147933434.jpg?imageView2/1/w/720/h/405/|imageMogr2/strip/interlace/1/quality/85/format/jpg","type":0,"news_type":0,"thumbnails":["https://img.huxiucdn.com/article/cover/202404/24/134147933434.jpg?imageView2/1/w/720/h/405/|imageMogr2/strip/interlace/1/quality/85/format/jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.huxiu.com/article/2946337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_huxiu","symbols":["BK4563","LU1861558580.USD","CRSP","BK4139","BK4588","LU1861559042.SGD","BK4556","BK4585","PAM","BK4081"],"gpt_icon":0},{"id":"2429113661","title":"Crispr Therapeutics Ag盘中异动 早盘急速拉升5.03%报58.46美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429113661","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429113661?lang=zh_cn&edition=full","pubTime":"2024-04-23 22:02","pubTimestamp":1713880938,"startTime":"0","endTime":"0","summary":"北京时间2024年04月23日22时02分，Crispr Therapeutics Ag股票出现波动，股价大幅拉升5.03%。截至发稿，该股报58.46美元/股，成交量13.5611万股，换手率0.16%，振幅4.74%。Crispr Therapeutics Ag股票所在的生物技术行业中，整体涨幅为1.43%。Crispr Therapeutics Ag公司简介：Crispr Therapeutics 是一家基因编辑公司，专注于开发基于 CRISPR/Cas9 的疗法。Crispr 的第一个获批药物是 Casgevy，该药物是与 Vertex Pharmaceuticals 合作开发的，针对镰状细胞病和输血依赖性β地中海贫血，这些疾病的医疗需求尚未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240423220219861e82ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240423220219861e82ed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRSP","LU1861559042.SGD","BK4585","BK4556","BK4588","LENZ","LU1861558580.USD","BK4139"],"gpt_icon":0},{"id":"2427709355","title":"或比CRISPR更安全更灵活，RNA编辑疗法加速发展-36氪","url":"https://stock-news.laohu8.com/highlight/detail?id=2427709355","media":"科技日报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2427709355?lang=zh_cn&edition=full","pubTime":"2024-04-15 08:12","pubTimestamp":1713139956,"startTime":"0","endTime":"0","summary":"据英国《自然》杂志网站近日报道，目前至少有3种RNA编辑疗法正在获批或已进入临床试验。支持者认为，该技术可能比CRISPR等基因组编辑技术更安全更灵活。与CRISPR基因组编辑不同，RNA编辑不会改变基因，也不会产生永久性的变化。美国伍兹霍尔海洋研究所生物实验室神经生物学家约书亚·罗森泰指出，这种短暂性可能会带来安全优势。因为能“剪切”DNA的CRISPR疗法的一个风险是脱靶效应，如果是RNA内出现脱靶效应，危险要小得多。（科技日报）","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415081241877ca281&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415081241877ca281&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","LU1861558580.USD","BK4505","KRKR","BK4139","BK4563","RNA","BK4077","CRSP","LU1861559042.SGD","BK4556"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.crisprtx.com","stockEarnings":[{"period":"1week","weight":-0.0507},{"period":"1month","weight":-0.0116},{"period":"3month","weight":-0.1778},{"period":"6month","weight":-0.1425},{"period":"1year","weight":-0.0557},{"period":"ytd","weight":-0.1515}],"compareEarnings":[{"period":"1week","weight":0.0077},{"period":"1month","weight":0.041},{"period":"3month","weight":0.057},{"period":"6month","weight":0.1749},{"period":"1year","weight":0.2371},{"period":"ytd","weight":0.1551}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"CRISPR Therapeutics AG作为一家瑞士股份公司在Inception Genomics AG名下于2013年10月31日注册成立。他们是一家领先的基因研究的公司，专注于CRISPR/Cas9的疗法发展。 CRISPR/ Cas9代表集群，定期相互间隔短回文重复（CRISPR）相关蛋白9，是改变基因的编排，基因组DNA的特定序列过程中的一项革命性的技术。他们正在应用此技术通过破坏，纠正或调节与疾病相关的基因来治疗广泛的稀有或常见的疾病。他们最先进的项目是针对β-地中海贫血和镰状细胞病，这种病症的治疗需要两个满足高医疗需求的血红蛋白。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.090159},{"month":2,"riseRate":0.625,"avgChangeRate":0.089566},{"month":3,"riseRate":0.25,"avgChangeRate":-0.077241},{"month":4,"riseRate":0.625,"avgChangeRate":-0.022564},{"month":5,"riseRate":0.625,"avgChangeRate":0.107663},{"month":6,"riseRate":0.75,"avgChangeRate":0.098677},{"month":7,"riseRate":0.625,"avgChangeRate":0.016206},{"month":8,"riseRate":0.571429,"avgChangeRate":0.019414},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.107923},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.054271},{"month":11,"riseRate":0.75,"avgChangeRate":0.223716},{"month":12,"riseRate":0.25,"avgChangeRate":-0.050604}],"exchange":"NASDAQ","name":"CRISPR Therapeutics AG","nameEN":"CRISPR Therapeutics AG"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CRISPR Therapeutics AG(CRSP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供CRISPR Therapeutics AG(CRSP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"CRISPR Therapeutics AG,CRSP,CRISPR Therapeutics AG股票,CRISPR Therapeutics AG股票老虎,CRISPR Therapeutics AG股票老虎国际,CRISPR Therapeutics AG行情,CRISPR Therapeutics AG股票行情,CRISPR Therapeutics AG股价,CRISPR Therapeutics AG股市,CRISPR Therapeutics AG股票价格,CRISPR Therapeutics AG股票交易,CRISPR Therapeutics AG股票购买,CRISPR Therapeutics AG股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CRISPR Therapeutics AG(CRSP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供CRISPR Therapeutics AG(CRSP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}